Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015, 159(1):018-026 | DOI: 10.5507/bp.2014.046

Prostate Specific Antigen. Current clinical application and future prospects

Katerina Duskova, Stepan Vesely
a Department of Urology, 2nd Faculty of Medicine, Charles University in Prague and University Hospital Motol, Czech Republic

Background: Prostate-specific antigen (PSA) is a glycoprotein produced by the prostate gland and its production can be enhanced in benign and malignant diseases. The introduction of PSA testing has greatly increased the detection of prostate cancer. However there is continuing controversy and confusion over the most appropriate application of the PSA test.

Methods: PubMed and Web of Science databases were used to search original and review articles on the historical aspects, clinical utilization and possible future directions in PSA.

Conclusions: After its discovery, PSA was quickly established as an exquisitely sensitive tumor marker for prostate cancer detection, assessment of treatment responses and follow-up among patients with prostate cancer. Nevertheless, controversy exists about the proper threshold for recommending prostate biopsy. If this limit is lowered to improve the sensitivity even more, patients with low-risk prostate cancer would be subsequently detected. Post-treatment PSA levels can certainly provide valuable information about the effectiveness of the therapy given. Recently introduced ultrasensitive PSA detection techniques are offering new insight into the changes in serum PSA at very low concentrations. This has resulted in identification of valuable postoperative prognostic variables together with the possibility of earlier cancer relapse detection. The development of assays that may show superior sensitivity and specificity in prostate cancer diagnosis is focused on proteins possibly complexed with PSA and other potential markers detectable both in serum and urine. The goal of newly discovered prostate cancer biomarkers is greater cancer specificity in order to reduce the overdiagnosis, overtreatment and financial cost.

Keywords: PSA, prostate cancer, biomarkers

Received: December 18, 2013; Accepted: August 29, 2014; Prepublished online: October 2, 2014; Published: March 9, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Duskova, K., & Vesely, S. (2015). Prostate Specific Antigen. Current clinical application and future prospects. Biomedical papers, 159(1), 018-026. doi: 10.5507/bp.2014.046
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Sokoll LJ, Chan DW. Prostate-specific antigen: its discovery and biochemical characteristic. Urol Clin North Am 1997;24(2):253-9. Go to original source... Go to PubMed...
    2. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317(15):909-16. Go to original source... Go to PubMed...
    3. Lilja H. Structure and function of prostatic and seminal vesicle-secreted proteins involved in the gelation and liquefaction of human semen. Scand J Clin Lab Invest Suppl 1988;191:13-20. Go to original source... Go to PubMed...
    4. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008;58(2):71-96. Go to original source... Go to PubMed...
    5. JE., Oesterling. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145(5):907-23. Go to original source... Go to PubMed...
    6. Oesterling JE, Chan DW, Epstein JI, Kimball AW Jr, Bruzek DJ, Rock RC, Bendler CB, Walsh PC. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 1988;139(4):766-722. Go to original source... Go to PubMed...
    7. Kort SA, Martens F, Vanpoucke H, van Duijnhoven HL, Blankenstein MA. Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation. Clin Chem 2006;52(8):1568-74. Go to original source... Go to PubMed...
    8. Roddam AW, Rimmer J , Nickerson C , Ward AM. Prostate-specific antigen: bias and molarity of commercial assays for PSA in use in England. Ann Clin Biochem 2006;43(1):35-48. Go to original source... Go to PubMed...
    9. Stephan C, Köpke T, Semjonow A, Lein M, Deger S, Schrader M, Miller K, Jung K. Discordant total and free prostate-specific antigen (PSA) assays: does calibration with WHO reference materials diminish the problem? Clin Chem Lab Med 2009;47(11):1325-31. Go to original source... Go to PubMed...
    10. Soletormos G, Semjonow A, Sibley PE. Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice. Clin Chem 2005;51(8):1342-51. Go to original source... Go to PubMed...
    11. Fitzpatrick JM, Banu E, Oudard S. Prostate-specific antigen kinetics in localized and advanced prostate cancer. BJU Int 2009;103(5):578-87. Go to original source... Go to PubMed...
    12. Blanchet J, Brinkmann T. The Clinical Impact of WHO Standardization of PSA Assays. J Med Biochem 2008;27:161-8. Go to original source...
    13. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004;350(22):2239-46. Go to original source... Go to PubMed...
    14. Chappell B, McLoughlin J. Technical considerations when obtaining and interpreting prostatic biopsies from men with suspicion of early prostate cancer: part I. BJU Int 2005;95(8):1135-40. Go to original source... Go to PubMed...
    15. Oesterling JE, Cooner WH, Jacobsen SJ, Guess HA, Lieber MM. Influence of patient age on the serum PSA concentration. An important clinical observation. Urol Clin North Am 1993;20(4):671-80. Go to PubMed...
    16. Catalona WJ, Hudson MA, Scardino PT, Richie JP, Ahmann FR, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol 1994;152(6Pt1):2037-42. Go to original source... Go to PubMed...
    17. Börgermann C, Loertzer H, Hammerer P, Fornara P, Graefen M, Rübben H. [Problems, objective, and substance of early detection of prostate cancer]. Urologe A 2010;49(2):181-9. Go to original source... Go to PubMed...
    18. Roobol MJ, Roobol DW, Schröder FH. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam). Urology 2005;65(2):343-6. Go to original source... Go to PubMed...
    19. S. Loeb, K.A. Roehl, J.A. Antenor, W.J. Catalona, B.K. Suarez, R.B. Nadler. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology 2006;67:316 Go to original source... Go to PubMed...
    20. Matthews GJ, Motta J, Fracehia JA. The accuracy of transrectal ultrasound prostate volume estimation: clinical correlations. J Clin Ultrasound 1996;24(9):501-5. Go to original source... Go to PubMed...
    21. Tang P, Du W, Xie K, Deng X, Fu J, Chen H, Yang W. Transition zone PSA density improves the prostate cancer detection rate both in PSA 4.0-10.0 and 10.1-20.0 ng/ml in Chinese men. Urol Oncol 2013;31(6):744-8. Go to original source... Go to PubMed...
    22. Vickers AJ, Till C, Tangen CM, Lilja H, Thompson IM. An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst 2011;103(6):462-9. Go to original source... Go to PubMed...
    23. O'Brien MF, Cronin AM, Fearn PA, Smith B, Stasi J, Guillonneau B, Scardino PT, Eastham JA, Vickers AJ, Lilja H. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clin Oncol 2009;27(22):3591-7. Go to original source... Go to PubMed...
    24. De Angelis G, Rittenhouse HG, Mikolajczyk SD, Blair Shamel L, Semjonow A. Twenty Years of PSA: From Prostate Antigen to Tumor Marker. Rev Urol 2007;9(3):113-23. Go to PubMed...
    25. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, Walsh PC, Scardino PT, Lange PH, Subong EN, Parson RE, Gasior GH, Loveland KG, Southwick PC. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998;279(19):1542-7. Go to original source... Go to PubMed...
    26. Stephan C, Lein M, Jung K, Schnorr D, Loening SA. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia. Cancer 1997;79(1):104-9. Go to original source... Go to PubMed...
    27. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Määttänen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360(13):1320-8. Go to original source... Go to PubMed...
    28. Loeb S, Vonesh EF, Metter EJ, Carter HB, Gann PH, Catalona WJ. What is the true number needed to screen and treat to save a life with prostate-specific antigen testing? J Clin Oncol 2011;29(4):464-7. Go to original source... Go to PubMed...
    29. Chodak GW, Thisted RA, Gerber GS, Johansson JE, Adolfsson J, Jones GW, Chisholm GD, Moskovitz B, Livne PM, Warner J. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994;330(4):242-8. Go to original source... Go to PubMed...
    30. Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, Nordling S, Häggman M, Andersson SO, Bratell S, Spångberg A, Palmgren J, Steineck G, Adami HO, Johansson JE. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011;364(18):1708-17. Go to original source... Go to PubMed...
    31. D'Amico AV, Ehittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280(11):969-74. Go to original source... Go to PubMed...
    32. Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ Jr, Dotan ZA, DiBlasio CJ, Reuther A, Klein EA, Kattan MW. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2005;23(28):7005-12. Go to original source... Go to PubMed...
    33. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294(4):433-9. Go to original source... Go to PubMed...
    34. Lughezzani G, Briganti A, Karakiewicz PI, Kattan MW, Montorsi F, Shariat SF, Vickers AJ. Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature. Eur Urol 2010;58(5):687-700. Go to original source... Go to PubMed...
    35. Semjonow A, Hamm M, Rathert P. Prediction of tumor recurrence after radical prostatectomy using elimination kinetics of prostate-specific antigen. World J Urol 1993;11(4):218-20. Go to original source... Go to PubMed...
    36. Roehl Ka, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3478 consecutive patients: long-term results. J Urol 2004;172(3):910-4. Go to original source... Go to PubMed...
    37. Partin AW, Pearson JD, Landis PK, Carter HB, Pound CR, Clemens JQ, Epstein JI, Walsh PC. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases.Urology 1994;43(5):649-59. Go to original source... Go to PubMed...
    38. Oefelein MG, Smith N, Carter M, Dalton D, Schaeffer A. The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies. J Urol 1995;154(6):2128-31. Go to original source... Go to PubMed...
    39. Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65(4):965-74. Go to original source... Go to PubMed...
    40. Bianco FJ Jr., Scardino PT, Eastham JA. Radical prostatectomy: Long-term cancer control and recovery of sexual and urinary function ("trifecta"). Urology 2005;66(5):83-94. Go to original source... Go to PubMed...
    41. Petros JA, Andriole GL. Serum PSA after antiandrogen therapy. Urol Clin North Am 1993;20(4):749-56. Go to original source... Go to PubMed...
    42. Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small EJ, Donnelly B, MacVicar G, Raghavan D and (INT-0162), Southwest Oncology Group Trial 9346. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006;24(24):3984-90. Go to original source... Go to PubMed...
    43. Bellmunt J, Rosenberg JE, Choueiri TK. Recent progress and pitfalls in testing novel agents in castration-resistant prostate cancer. Eur Urol 2009;56(4):606-8. Go to original source... Go to PubMed...
    44. Boccon-Gibod L. pT3 prostate cancer: The case for salvage (as opposed to adjuvant) radiation therapy. Eur Urol Suppl 2007;54(3):541-2. Go to original source...
    45. Bock JL, Klee GG. How sensitive is a prostate specific antigen measurement? How sensitive does it need to be? Arch Pathol Lab Med 2004;128:341-3. Go to original source...
    46. Hong SK, Park HZ, Lee WK, Kim DS, Lee JS, Doo SH, Jeong SJ, Yoon CY, Byun SS, Lee SE. Prognostic significance of undetectable ultrasensitive prostate-specific antigen nadir after radical prostatectomy. Urology 2010;76(3):723-7. Go to original source... Go to PubMed...
    47. Taylor JA III, Koff SG, Dauser DA, McLeod DG. The relationship of ultrasensitive measurements of prostate-specific antigen levels to prostate cancer recurrence after radical prostatectomy. BJU Int 2006;98(3):540-3. Go to original source... Go to PubMed...
    48. Salagierski M, Schalken JA. Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion. J Urol 2012;187(3):795-801. Go to original source... Go to PubMed...
    49. van Gils MP, Hessels D, van Hooij O, Jannink SA, Peelen WP, Hanssen SL, Witjes JA, Cornel EB, Karthaus HF, Smits GA, Dijkman GA, Mulders PF, Schalken JA. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res 2007;13:939-43. Go to original source... Go to PubMed...
    50. Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C, Brentano S, Mathis J, Pham J, Meyer T, Cass M, Hodge P, Macairan ML, Marks LS, Rittenhouse H. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006;52(6):1089-95. Go to original source... Go to PubMed...
    51. van Gils MP, Hessels D, van Hooij O, Jannink SA, Peelen WP, Hanssen SL, Witjes JA, Cornel EB, Karthaus HF, Smits GA, Dijkman GA, Mulders PF, Schalken JA. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res 2007;13(3):939-43. Go to original source... Go to PubMed...
    52. Zielie PJ, Mobley JA, Ebb RG, Jiang Z, Blute RD, Ho SM. A novel diagnostic test for prostate cancer emerges from the determination of alpha-methylacyl-coenzyme a racemase in prostatic secretions. J Urol 2004;172(3):1130-3. Go to original source... Go to PubMed...
    53. Laxman B, Tomlins SA, Mehra R, Morris DS, Wang L, Helgeson BE, Shah RB, Rubin MA, Wei JT, Chinnaiyan AM. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 2006;8(10):885-8. Go to original source... Go to PubMed...
    54. Masood A Khan, MD and Alan W Partin. Evolving Role of Pro-PSA as a New Serum Marker for the Early Detection of Prostate Cancer. Rev Urol 2002;4(4):198-200. Go to PubMed...
    55. Mikolajczyk SD, Millar LS, Wang TJ. "BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology 2000;55(1):41-5. Go to original source... Go to PubMed...
    56. Mikolajczyk SD, Marks LS, Partin AW. Free prostate-specific antigen in serum is becoming more complex. Urology 2002;59(6):797-802. Go to original source... Go to PubMed...
    57. Nurmikko P, Väisänen V, Piironen T, Lindgren S, Lilja H, Pettersson K. Production and characterization of novel anti-prostate-specific antigen (PSA) monoclonal antibodies that do not detect internally cleaved Lys145-Lys146 inactive PSA. Clin Chem 2000;46(10):1610-8. Go to original source...
    58. Leman ES, Cannon GW, Trock BJ, Sokoll LJ, Chan DW, Mangold L, Partin AW, Getzenberg RH. EPCA-2: a highly specific serum marker for prostate cancer. Urology 2007;69(4):714-20. Go to original source... Go to PubMed...
    59. Perner S, Hofer DM, Kim R, Shah RB, Li H, Möller P, Hautmann RE, Gschwend JE, Kuefer R, Rubin MA. Prostate-specific membrane antigen expression as a predictor of a prostate cancer progression. Hum Pathol 2007;38(5):696-701. Go to original source... Go to PubMed...
    60. Whitaker HC, Warren AY, Eeles R, Kote-Jarai Z, Neal DE. The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target. Prostate 2010;70(3):333-40. Go to original source... Go to PubMed...
    61. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310(5748):644-8. Go to original source... Go to PubMed...
    62. Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB, Schalken JA. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 2007;13(17):5103-8. Go to original source... Go to PubMed...
    63. Graves HC, Sensabaugh GF, Blake ET. Postcoital detection of a male-specific semen protein. Application to the investigation of rape. N Engl J Med 1985;312:338-43. Go to original source... Go to PubMed...
    64. Sağlam HS, Köse O, Özdemir F, Adsan O. Do the values of prostate specific antigen obtained from fresh and dried urine reflect the serum measurements. Urology. 2013;5:99-101.
    65. Irani J, Salomon L, Soulié M, Zlotta A, de la Taille A, Doré B, Millet C. Urinary/serum prostate-specific antigen ratio: Comparison with free/total serum prostate-specific antigen ratio in improving prostate cancer detection. Urology. 2005;65:533-7. Go to original source... Go to PubMed...
    66. Chwatko G, Forma E, Wilkocz J, G³owacki R, Jó¼wiak P, Ró¿añski W, Bry¶ M, Krze¶lak A. Thiosulfate in urine as a facilitator in the diagnosis of prostate cancer for patients with prostate-specific antigen less or equal 10 ng/mL. Clin Chem Lab Med 2013;51:1825-31 Go to original source... Go to PubMed...
    67. Jung K, Reszka R, Kamlage B, Bethan B, Stephan C, Lein M, Kristiansen G. Tissue metabolite profiling identifies differentiating and prognostic biomarkers for prostate carcinoma. Int J Cancer 2013;133(12):2914-24. Go to original source... Go to PubMed...
    68. Hemminki K, Ji J, Försti A, Sundquist J, Lenner P. Concordance of survival in family members with prostate cancer. J Clin Oncol. 2008;26(10):1705-9. Go to original source... Go to PubMed...
    69. Gudmundsson J, Besenbacher S, Sulem P, Gudbjartsson D, Olafsson I, Arinbjarnarson S. Genetic correction of PSA values using sequence variants associated with PSA levels. Sci Transl Med 2010;2(62):62-92 Go to original source... Go to PubMed...
    70. Carter BS, Bova GS, Beaty TH, Steinberg GD, Childs B, Isaacs WB, Walsh PC. Hereditary prostate cancer: epidemiologic and clinical features. J Urol 1993;150(3):797-802. Go to original source... Go to PubMed...
    71. Bookstein R, Totowa NJ. Tumor suppressor genes in prostate cancer. In: Bookstein R, Totowa NJ, editors. Prostate cancer: biology genetics and the new therapeutics. Humana Press; 2001. p. 61-93. Go to original source...
    72. Thompson EB. The many roles of c-Myc in apoptosis. Annu Rev Physiol 1998;60:575-600. Go to original source... Go to PubMed...
    73. Sato K, Qian J, Slezak JM, Lieber MM, Bostwick DG, Bergstralh EJ, Jenkins RB. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J Natl Cancer Inst 1999;91(18):1574-80. Go to original source... Go to PubMed...
    74. Karayi MK1, Markham AF. Molecular biology of prostate cancer. Prostate Cancer Prostatic Dis. 2004;7(1):6-20. Go to PubMed...
    75. Sanchez KM, Sweeney CJ, Mass R, Koch MO, Eckert GJ, Geary WA, Baldridge LA, Zhang S, Eble JN, Cheng L. Evaluation of HER-2/neu expression in prostatic adenocarcinoma: a requested for a standardized, organ specific methodology. Cancer 2002;95(8):1650-5. Go to original source... Go to PubMed...
    76. Lara PN, Jr, Meyers FJ, Gray CR, Edwards RG, Gumerlock PH, Kauderer C, Tichauer G, Twardowski P, Doroshow JH, Gandara DR. HER-2/neu is overexpressed infrequently in patients with prostate carcinoma. Results from the California Cancer Consortium Screening Trial. Cancer 2002;94(10):2584-9. Go to original source... Go to PubMed...
    77. Catz SD, Johnson JL. BCL-2 in prostate cancer: a minireview. Apoptosis 2003;8(1):29-37. Go to original source... Go to PubMed...
    78. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52(24):6940-4. Go to PubMed...
    79. Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, Wahl M, Nisitani S, Yamashiro J, Le Beau MM, Loda M, Witte ON. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA 1998;95(4):1735-40. Go to original source... Go to PubMed...
    80. Gu Z, Thomas G, Yamashiro J, Shintaku IP, Dorey F, Raitano A, Witte ON, Said JW, Loda M, Reiter RE. Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 2000;19(10):1288-96. Go to original source... Go to PubMed...
    81. Hughes C, Murphy A, Martin C, Sheils O, O'Leary J. Molecular pathology of prostate cancer. J Clin Pathol 2005;58(7):673-84. Go to original source... Go to PubMed...
    82. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 1993;53(14):3369-73.
    83. Rogler A, Rogenhofer M, Borchardt A, Lunz JC, Knoell A, Hofstaedter F, Tannapfel A, Wieland W, Hartmann A, Stoehr R. P53 codon 72 (Arg72Pro) polymorphism and prostate cancer risk: association between disease onset and proline genotype. Pathobiology 2011;78(4):193-200. Go to original source... Go to PubMed...
    84. Sun H, Lesche R, Li DM, Liliental J, Zhang H, Gao J, Gavrilova N, Mueller B, Liu X, Wu H. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci USA 1999;96(11):6199-204. Go to original source... Go to PubMed...
    85. Hughes C, Murphy A, Martin C, Sheils O, O'Leary J. Molecular pathology of prostate cancer. J Clin Pathol 2005;58(7):673-84. Go to original source... Go to PubMed...
    86. Doherty AP, Bower M, Smith GL, Miano R, Mannion EM, Mitchell H, Christmas TJ. Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival. Brit J Cancer 2000;83:1432-6. Go to original source... Go to PubMed...
    87. Nakamura M, Hasumi H, Miyoshi Y, Sugiura S, Fujinami K, Yao M, Kubota Y, Uemura H. Usefulness of ultrasensitive prostate-specific antigen assay for early detection of biochemical failure after radical prostatectomy. Int J Urol 2005;12:1050-4. Go to original source... Go to PubMed...
    88. Shen S, Lepor H, Yaffee R, Taneja SS. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy. J Urol 2005;173:777-80. Go to original source... Go to PubMed...
    89. Sakai I, Harada K, Kurahashi T, Muramaki M, Yamanaka K, Hara I, Inoue TA, Miyake H. Usefulness of the nadir value of serum prostate-specific antigen measured by an ultrasensitive assay as a predictor of biochemical recurrence after radical prostatectomy for clinically localized prostate cancer. Urol Int 2006;76:227-31. Go to original source... Go to PubMed...
    90. Kinoshita H, Kamoto T, Nishiyama H, Nakamura E, Matsuda T, Ogawa O. Prostate specific antigen nadir determined using ultra-sensitive prostate specific antigen as a predictor of biochemical progression after radical prostatectomy in Japanese males. Int J Urol 2007;14(10):930-4. Go to original source... Go to PubMed...
    91. Eisenberg ML, Davies BJ, Cooperberg MR, Cowan JE, Carroll PR. Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy. Eur Urol 2010;57(4):622-9. Go to original source... Go to PubMed...
    92. Yoshida T, Matsuzaki K, Kobayashi Y, Takeda K, Nakayama M, Arai Y, Kakimoto K, Nishimura K. Usefulness of postoperative nadir prostate-specific antigen value by ultrasensitive assay as a predictor of prostate-specific antigen relapse for pathological T3 or positive surgical margins after radical prostatectomy for prostate cancer. Int Urol Nephrol 2012;44(2):479-85. Go to original source... Go to PubMed...
    93. Vesely S, Jarolim L, Schmidt M, Minarik I, Dusek P, Babjuk M. Parameters derived from the postoperative decline in ultrasensitive PSA improve the prediction of radical prostatectomy outcome. World J Urol 2013;31(2):299-304. Go to original source... Go to PubMed...

    Return to the content